Marie Sherlock (Dublin Central, Labour)
Link to this: Individually | In context | Oireachtas source

201. To ask the Minister for Health if she will sanction a HIQA review on the effectiveness of continuous glucose monitoring for type 2 diabetes; and if she will make a statement on the matter. [6793/26]

Jennifer Carroll MacNeill (Dún Laoghaire, Fine Gael)
Link to this: Individually | In context | Oireachtas source

In Ireland, Health Technology Assessments (HTAs) are used to help decide which health technologies (such as drugs, medical tests, medical devices, surgeries, healthcare reorganisation) should be used and funded in our public healthcare system. A HTA looks at the effectiveness, safety and cost of different health technologies.

HIQA has a statutory remit to evaluate the clinical and cost effectiveness of health technologies and provide advice to the Minister for Health and to the Health Service Executive (HSE). It is recognised that the findings of a HTA may have implications for other key stakeholders in the Irish healthcare system, such as patient groups, the general public, clinicians, other healthcare providers, academic groups, and the manufacturing industry.

Under the Health (Pricing and Supply of Medical Goods) Act 2013, the HSE has statutory responsibility for decisions on the pricing and reimbursement of medicines and medical devices. The HSE has advised that the HSE-Medicines Management Programme and the National Clinical Programme for Diabetes, with the support of the HSE’s Chief Clinical Officer, has submitted a joint proposal requesting HIQA to consider a HTA of CGM for patients with insulin-dependent diabetes in their 2026 workplan. The outcome of a HTA could support a decision by the HSE under the Health (Pricing and Supply of Medical Goods) Act, 2013 regarding long-term funding and the availability of this technology for patients.